Martindale Pharma is entering the woundcare market for the first time with the launch of a novel hydroconductive wound dressing based on patented LevaFiber technology.
Drawtex made its debut at the Wounds UK conference earlier this month and utilises advanced materials technology to rapidly and effectively lift, hold and transfer exudate and necrotic tissue away from the wound.
This shortens the time taken to create a healthy wound bed, making the product ideal in the treatment of moderate to heavily exudating chronic wounds, including diabetic foot ulcers and chronic venous leg ulcers.
Martindale Pharma has stated its intention of building a "broad and diverse product portfolio" in the UK woundcare market, which was valued at 150 million pounds in 2011.
Richard de Souza, chief executive officer of Martindale Pharma, said: "Our expertise and heritage in the manufacture and supply of high-quality innovative medicines ... makes Martindale Pharma the ideal partner to provide high-quality woundcare products."
Earlier this month, the company announced the launch of new formulations of its physeptone and methadone products, which will be appearing in pharmacies across the UK this week.See all the latest jobs in Consumer